SCHEMBL25549481

SCHEMBL25549481

C(=C/c1ccccc1)\CO/N=C(\Cn1ccnc1)c1ccc2c(c1)OCO2

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TBXA2R P21731 5/20 0.44
MT-CO2 P00403 1/20 0.44
NPC1 O15118 3/20 0.41
RAB9A P51151 3/20 0.41
MAPT P10636 1/20 0.41
TBXAS1 P24557 5/20 0.41
ALOX15 P16050 2/20 0.39
TSHR P16473 1/20 0.39
MAPK1 P28482 1/20 0.39
CYP3A4 P08684 2/20 0.37
CYP2D6 P10635 2/20 0.37
PGR P06401 1/20 0.37
CHRM2 P08172 1/20 0.37
HTR1A P08908 1/20 0.37
ADRA2A P08913 1/20 0.37
ADORA3 P0DMS8 1/20 0.37
AR P10275 1/20 0.37
CHRM1 P11229 1/20 0.37
CYP2C9 P11712 1/20 0.37
ADRB3 P13945 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25549436 0.85 MT-CO2 (0.43) TBXA2RMT-CO2NPC1RAB9AMAPT
SCHEMBL25549442 0.84 TBXA2R (0.48) TBXA2RMT-CO2NPC1RAB9AMAPT
SCHEMBL25549432 0.83 MT-CO2 (0.44) TBXA2RMT-CO2NPC1RAB9AMAPT
SCHEMBL25549486 0.80 MT-CO2 (0.47) TBXA2RMT-CO2NPC1RAB9AMAPT
SCHEMBL25549438 0.79 MT-CO2 (0.43) TBXA2RMT-CO2NPC1RAB9AMAPT
SCHEMBL25549433 0.78 MT-CO2 (0.47) TBXA2RMT-CO2NPC1RAB9AMAPT
SCHEMBL25549441 0.78 MT-CO2 (0.43) TBXA2RMT-CO2RAB9AMAPTTBXAS1
SCHEMBL25191205 0.77 ALOX15 (0.47) MT-CO2NPC1RAB9AALOX15MAPK1
SCHEMBL25549452 0.77 ALOX15 (0.47) MT-CO2NPC1RAB9AALOX15MAPK1
SCHEMBL25549439 0.77 MT-CO2 (0.43) TBXA2RMT-CO2NPC1RAB9AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11680062-B2 3,4-methylenedioxyphenylimidazolylethanonexime ether derivative, preparation method and use thereof, and drug for the treatment of Alzheimer's disease NORTHWEST A & F UNIVERSITY (CN) 2023-06-20 US disclosed
US-11680062-B2 3,4-methylenedioxyphenylimidazolylethanonexime ether derivative, preparation method and use thereof, and drug for the treatment of Alzheimer's disease NORTHWEST A & F UNIVERSITY (CN) 2023-06-20 US disclosed
US-20230159503-A1 3,4-METHYLENEDIOXYPHENYLIMIDAZOLYLETHANONEXIME ETHER DERIVATIVE, PREPARATION METHOD AND USE THEREOF, AND DRUG FOR THE TREATMENT OF ALZHEIMER'S DISEASE NORTHWEST A & F UNIVERSITY (CN) 2023-05-25 US disclosed
US-20230159503-A1 3,4-METHYLENEDIOXYPHENYLIMIDAZOLYLETHANONEXIME ETHER DERIVATIVE, PREPARATION METHOD AND USE THEREOF, AND DRUG FOR THE TREATMENT OF ALZHEIMER'S DISEASE NORTHWEST A & F UNIVERSITY (CN) 2023-05-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230159503-A1 3,4-METHYLENEDIOXYPHENYLIMIDAZOLYLETHANONEXIME ETHER DERIVATIVE, PREPARATION METHOD AND USE THEREOF, AND DRUG FOR THE TREATMENT OF ALZHEIMER'S DISEASE NOS3, CYP51A1, NOS1 TBXA2R 1766/4885MT-CO2 351/4885NPC1 2578/4885
US-11680062-B2 3,4-methylenedioxyphenylimidazolylethanonexime ether derivative, preparation method and use thereof, and drug for the treatment of Alzheimer's disease NOS3, CYP51A1, NOS1 TBXA2R 1766/4885MT-CO2 351/4885NPC1 2578/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.